Related Experiment Video
Updated: May 18, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Published on: June 27, 2015
Dialysate calcium individualisation: a pending issue
Francisco Maduell1, Néstor Rodríguez, Marta Arias-Guillén
1Servicio de Nefrología y Trasplante Renal, Hospital Clínic, Barcelona, Spain. fmaduell@clinic.ub.es
Insights
Individualizing dialysate calcium is crucial for managing cardiovascular risk in dialysis patients. Adjusting dialysate calcium concentrations based on pre- and post-dialysis calcium levels optimizes patient outcomes and mineral metabolism control.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Mineral Metabolism
Background:
- Calcium plays a vital role in dialysis patients, significantly impacting cardiovascular risk.
- Recent shifts in phosphate binder and calcimimetic use have altered target pre-dialysis serum calcium levels.
- Accurate assessment of intradialytic calcium changes is essential for personalized dialysis prescriptions.
Purpose of the Study:
- To evaluate intradialytic calcium (Ca) shifts with varying dialysate calcium concentrations.
- To determine the implications of these shifts on calcium-phosphate metabolism control.
- To inform individualized dialysis prescription strategies.
Main Methods:
- A study involving 98 hemodialysis patients (68 male, 30 female) with a mean age of 59.3 years.
- Patients underwent two hemodialysis sessions using dialysate calcium concentrations of 2.5 mEq/l (Ca25) and 3.0 mEq/l (Ca30).
- Pre- and post-dialysis calcium, phosphorus, and parathyroid hormone (PTH) levels were measured, with patients categorized by pre-dialysis calcium levels.
Main Results:
- No significant differences in pre-dialysis calcium, phosphorus, or PTH were observed between Ca25 and Ca30 groups.
- The Ca30 dialysate significantly increased post-dialysis calcium and decreased PTH, while Ca25 showed no significant changes in post-dialysis calcium or PTH.
- With Ca25, intradialytic calcium increased in patients with pre-dialysis calcium <9.0 mg/dl and decreased in those >9.5 mg/dl, whereas Ca30 increased calcium in all subgroups.
Conclusions:
- Dialysate calcium prescription requires individualization based on pre- and post-dialysis calcium levels.
- The goal is to achieve desired changes (increase, decrease, or no change) in post-dialysis calcium.
- Personalized adjustments are key to effectively managing the calcium-phosphate metabolism in dialysis patients.
Unlabelled:
Calcium is one of the key elements to consider in patients on dialysis due to its relationship with cardiovascular risk. The introduction of non-calcium-based phosphate binders and calcimimetics has changed the setting for pre-dialysis serum calcium in recent years from 9.5-10.5mg/dl to 8.5-9.5mg/dl. To assess more accurately the changes in calcium (Ca) during haemodialysis sessions and to individualise prescriptions, the aim of this study was to assess the intradialytic changes of two different dialysate Ca concentrations before and after hemodialysis and their implications in controlling calcium-phosphate metabolism.
Patients And Method:
We analysed 98 patients with a mean age of 59.3 ± 15 years, 68 of which were men and 30 women. Each patient received two HD sessions with two different dialysate Ca concentrations: 2.5 mEq/l (Ca25 group) or 3.0 mEq/l (Ca30 group). Pre- and post-dialysis Ca, phosphorus (P) and PTH were determined, and associated medications were recorded. For a more individualised analysis, patients were divided into four subgroups of Ca<8.5mg/dl, 8.5-9.0mg/dl, 9.0-9.5mg/dl, and >9.5mg/dl, according to pre-dialysis serum calcium levels.
Results:
There were no differences in pre-dialysis values of Ca: 8.81 ± 0.65 (CA25) and 8.88 ± 0.61 (CA30), P: 4.01 ± 1.3 (CA25) and 4.19 ± 1.2 (CA30), or PTH: 352 ± 288 (CA25) and 369 ± 310 (CA30). Post-dialysis Ca and PTH did not change significantly with CA25 dialysate, although there was a significant post-dialysis Ca increase to 10.2 ± 0.6 (P<.001) accompanied by a decrease in post-dialysis PTH (181 ± 227, P<.001) with CA30. However, with CA25 dialysate, when different subgroups of pre-dialysis Ca were analysed: <8.5mg/dl (30.6%), 8.5-9.0mg/dl (31.6%), 9.1-9.5mg/dl (23.5%) and >9.5mg/dl (14.3%) we observed a Ca increase during the session in the <8.5 (P<.001) and 8.5-9.0 (P<.01) subgroups. Ca was unchanged in the 9.1-9.5 group and Ca decreased when the initial Ca values were >9.5mg/dL (P<.01). A Ca increase (P<.001) and a decrease in PTH (P<.01) were observed in all subgroups with CA30 dialysate. A total of 42% of patients were taking calcimimetics, 47% paricalcitol, and 32% calcium-based phosphate binders, although these drugs were not linked with pre- or post-dialysis Ca levels in or dialysate treatment.
Conclusion:
We concluded that the prescription of Ca dialysate needs to be individualised based on pre- and post-dialysis Ca values and the need for an increase, decrease, or no changes in post-dialysis calcium in relation to the clinical condition of the patient's phosphorous-calcium metabolism.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Hemodialysis III: Nursing Management
Factors Affecting Solubility
Skeleton and Calcium Homeostasis
Peritoneal Dialysis III: Nursing Management
Dialysis
